{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T12:14:04Z","timestamp":1715948044188},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,1,7]],"date-time":"2004-01-07T00:00:00Z","timestamp":1073433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2004,4]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Perhexiline is an antianginal agent that displays both saturable and polymorphic metabolism via CYP2D6. The aim of this study was to determine whether perhexiline produces clinically significant inhibition of CYP2D6\u2010catalysed metabolism in angina patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The effects of perhexiline on CYP2D6\u2010catalysed metabolism were investigated by comparing urinary total dextrorphan\/dextromethorphan metabolic ratios following a single dose of dextromethorphan (16.4\u2003mg) in eight matched control patients not taking perhexiline and 24 patients taking perhexiline. All of the patients taking perhexiline had blood drawn for <jats:italic>CYP2D6<\/jats:italic> genotyping as well as to measure plasma perhexiline and <jats:italic>cis<\/jats:italic>\u2010OH\u2010perhexiline concentrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median (range) dextrorphan\/dextromethorphan metabolic ratios were significantly higher (<jats:italic>P\u2003&lt;<\/jats:italic>\u20030.0001) in control patients, 271.1 (40.3\u2013686.1), compared with perhexiline\u2010treated patients, 5.0 (0.3\u2013107.9). In the perhexiline\u2010treated group 10\/24 patients had metabolic ratios consistent with poor metabolizer phenotypes; however, none was a genotypic poor metabolizer. Interestingly, 89% of patients who had phenocopied to poor metabolizers had only one functional <jats:italic>CYP2D6<\/jats:italic> gene. There was a significant negative linear correlation between the log of the dextrorphan\/dextromethorphan metabolic ratio and plasma perhexiline concentrations (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>\u2003=\u20030.69, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001). Compared with patients with at least two functional <jats:italic>CYP2D6<\/jats:italic> genes, those with one functional gene were on similar perhexiline dosage regimens but had significantly higher plasma perhexiline concentrations, 0.73 (0.21\u20131.00) <jats:italic>vs.<\/jats:italic> 0.36 (0.04\u20130.69)\u2003mg\u2003l<jats:sup>\u22121<\/jats:sup> (<jats:italic>P\u2003<\/jats:italic>=\u20030.04), lower <jats:italic>cis<\/jats:italic>\u2010OH\u2010perhexiline\/perhexiline ratios, 2.85 (0.35\u20136.10) <jats:italic>vs.<\/jats:italic> 6.51 (1.84\u201311.67) (<jats:italic>P\u2003=<\/jats:italic>\u20030.03), and lower dextrorphan\/dextromethorphan metabolic ratios, 2.51 (0.33\u201339.56) <jats:italic>vs.<\/jats:italic> 11.80 (2.90\u201336.93) (<jats:italic>P\u2003=<\/jats:italic>\u20030.005).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Perhexiline significantly inhibits CYP2D6\u2010catalysed metabolism in angina patients. The plasma <jats:italic>cis<\/jats:italic>\u2010OH\u2010perhexiline\/perhexiline ratio may help to both phenotype patients and predict those in whom perhexiline may be most likely to cause clinically significant metabolic inhibition.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2125.2003.02033.x","type":"journal-article","created":{"date-parts":[[2004,12,20]],"date-time":"2004-12-20T20:42:40Z","timestamp":1103575360000},"page":"456-463","source":"Crossref","is-referenced-by-count":6,"title":["Clinical inhibition of CYP2D6\u2010catalysed metabolism by the antianginal agent perhexiline"],"prefix":"10.1111","volume":"57","author":[{"given":"Benjamin J. L.","family":"Davies","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet K.","family":"Coller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather M.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gillis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew A.","family":"Somogyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond G.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta C.","family":"Sallustio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,1,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(96)00204-3"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200012000-00016"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02089960"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.284.6312.295"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.25.10.1057"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5273(86)90146-4"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.81.4.1260"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01805.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.21.1.27"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600700325"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1982.tb02514.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01618.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/10826079208020880"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199612000-00002"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2002.3296"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/00048679709065084"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04348.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.235"},{"key":"e_1_2_7_20_2","first-page":"284","article-title":"Cytochrome P450 2D6 variants in a caucasian population: allele frequencies and phenotypic consequences","volume":"60","author":"Sachse C","year":"1997","journal-title":"Am J Hum Genet"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01213011-199912000-00002"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1373\/49.4.542"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199001000-00018"},{"key":"e_1_2_7_24_2","first-page":"S138","article-title":"Identification of CYP2D6 genotype via a new sequencing protocol","volume":"97","author":"Coller JK","year":"2003","journal-title":"Chemicke Listy"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92086-W"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199802000-00003"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(98)00567-8"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb05430.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90056-9"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200007000-00006"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127000004000108"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1986.tb05250.x"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb05666.x"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199005000-00016"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200110000-00004"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200110000-00002"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2003.02033.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.2003.02033.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T12:56:41Z","timestamp":1697374601000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.2003.02033.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1046\/j.1365-2125.2003.02033.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.2003.02033.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,7]]}}}